About Sucraid

Sucraid Is an Effective Treatment for CSID

Three clinical trials have evaluated the therapeutic benefits of sacrosidase (the generic name for Sucraid).

In This Section
Clinical Trial 1

The first study was designed to determine the ability of a replacement enzyme for sucrase to improve the gastrointestinal (GI) symptoms of study participants diagnosed with Congenital Sucrase-Isomaltase Deficiency (CSID).

The therapeutic benefit of the replacement enzyme was measured by the hydrogen breath test, which measures the activity of the sucrase enzyme (see the breath tests). This study also measured the ability of four different doses of the replacement enzyme sacrosidase to relieve GI symptoms associated with CSID. The study included 28 patients with confirmed CSID. In CSID patients up to 3 years of age, 86% had complete relief from their symptoms. In patients over 3 years of age, 77% had complete relief of their symptoms. The study showed that sacrosidase was effective at relieving GI symptoms in patients with CSID and was most effective at the highest doses.1

Clinical Trial 2

In the second clinical trial, the researchers also used the hydrogen breath test to measure the ability of sacrosidase, taken by the study participants diagnosed with CSID.

The relief of GI symptoms was also measured after treatment with four different doses of sacrosidase. The researchers concluded that sacrosidase is an effective and well-tolerated treatment for sucrase deficiency associated with CSID. Patients showed a marked decrease in the hydrogen breath test results when they received sacrosidase in comparison to placebo indicating that the sacrosidase was working to help digest sucrose.2

Clinical Trial 3

The third clinical trial was conducted over a period of several years in 32 participants diagnosed with CSID and treated with Sucraid.

The researchers again found therapy with Sucraid to be well-tolerated and effective in reducing the GI symptoms of sucrase deficiency associated with CSID. Study participants in this long-term study spanned a broad range of ages. While taking Sucraid, the study participants consumed a normal, sucrose-containing diet and experienced fewer GI symptoms than before therapy with Sucraid.3

Learn How You Can Get Sucraid from Our Specialty Pharmacy

Important Safety Information for Sucraid® (sacrosidase) Oral Solution

  • Sucraid may cause a serious allergic reaction. If you notice any swelling or have difficulty breathing, get emergency help right away.
  • Sucraid does not break down some sugars that come from the digestion of starch. You may need to restrict the amount of starch in your diet. Your doctor will tell you if you should restrict starch in your diet.
  • Tell your doctor if you are allergic to, have ever had a reaction to, or have ever had difficulty taking yeast, yeast products, papain, or glycerin (glycerol).
  • Tell your doctor if you have diabetes, as your blood glucose levels may change if you begin taking Sucraid. Your doctor will tell you if your diet or diabetes medicines need to be changed.
  • Some patients treated with Sucraid may have worse abdominal pain, vomiting, nausea, or diarrhea. Constipation, difficulty sleeping, headache, nervousness, and dehydration have also occurred in patients treated with Sucraid. Check with your doctor if you notice these or other side effects.
  • Sucraid has not been tested to see if it works in patients with secondary (acquired) sucrase deficiency.
  • NEVER HEAT SUCRAID OR PUT IT IN WARM OR HOT BEVERAGES OR INFANT FORMULA. Do not mix Sucraid with fruit juice or take it with fruit juice. Take Sucraid as prescribed by your doctor. Normally, half the dose of Sucraid is taken before a meal or snack and the other half is taken during the meal or snack.
  • Sucraid should be refrigerated at 36°F-46°F (2°C-8°C) and should be protected from heat and light.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.FDA.gov/medwatch or call 1-800-FDA-1088.

Indication

Sucraid® (sacrosidase) Oral Solution is an enzyme replacement therapy for the treatment of genetically determined sucrase deficiency, which is part of Congenital Sucrase-Isomaltase Deficiency (CSID).